Groeben C, Baunacke M, Borkowetz A, Kliesch S, Wülfing C, Ihrig A, Huber J
Klinik und Poliklinik für Urologie, Medizinische Fakultät Carl Gustav Carus, TU Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland.
Centrum für Reproduktionsmedizin und Andrologie, Abteilung für Klinische Andrologie, Universitätsklinikum Münster, Münster, Deutschland.
Urologe A. 2016 Jun;55(6):784-91. doi: 10.1007/s00120-016-0054-0.
Treatment decision making remains a complex task for localized prostate cancer. Decision aids for patients can support the medical consultation. However, it is not known if German urologists accept decision aids for patients. Comparative data exist from a current survey among american urologists and radio oncologists.
From October through November 2014 we conducted an online survey consisting of 11 multiple-choice questions and an optional free text commentary among the members of DGU and BDU. All data was processed anonymously. We received 464 complete responses for a 6.6 % return rate. For group comparison we applied the Chi2-test.
Respondents' median age was 50 (range 26-87) years and 15 % were female. 7 % were residents, 31 % employed at a clinic, and 57 % in private practice. Due to the low response rate of younger colleagues the results were not representative for the basic population. Regardless of age (p = 0.2) and professional environment (p = 1) shared decision making was preferred by 89 %. When counseling their patients with localized prostate cancer 20 % relied exclusively on conversation. To support their conversation 63 % used print media, 49 % decision aids, 33 % contact offers to support groups, 24 % Internet resources and 13 % video material. From using decision aids 86 % expected positive effects for patients and 78 % for physicians (p = 0.017). 15 % expected a change of the treatment decision. 77 % would motivate their patients to use a decision aid.
In comparison to the opinion of american urologists and radio oncologists the acceptance of decision aids for patients among German urologists is significantly higher.
对于局限性前列腺癌,治疗决策仍然是一项复杂的任务。为患者提供的决策辅助工具有助于医疗咨询。然而,尚不清楚德国泌尿科医生是否接受为患者提供的决策辅助工具。目前有来自美国泌尿科医生和放射肿瘤学家的比较数据。
2014年10月至11月,我们对德国泌尿外科学会(DGU)和德国男科学会(BDU)的成员进行了一项在线调查,该调查包括11个多项选择题和一个可选的自由文本评论。所有数据均匿名处理。我们收到了464份完整回复,回复率为6.6%。为进行组间比较,我们应用了卡方检验。
受访者的中位年龄为50岁(范围26 - 87岁),15%为女性。7%为住院医生,31%受雇于诊所,57%从事私人执业。由于年轻同事的回复率较低,结果不代表基础人群。无论年龄(p = 0.2)和专业环境(p = 1)如何,89%的人更喜欢共同决策。在为局限性前列腺癌患者提供咨询时,20%的人仅依靠谈话。为辅助谈话,63%的人使用印刷媒体,49%的人使用决策辅助工具,33%的人提供与支持小组的联系,24%的人使用互联网资源,13%的人使用视频材料。在使用决策辅助工具的人中,86%预计对患者有积极影响,78%预计对医生有积极影响(p = 0.017)。15%的人预计会改变治疗决策。77%的人会鼓励他们的患者使用决策辅助工具。
与美国泌尿科医生和放射肿瘤学家的观点相比,德国泌尿科医生对为患者提供决策辅助工具的接受度明显更高。